title: Development of poly(Lactic acid)/chitosan co-matrix microspheres: controlled release of taxol-heparin for preventing restenosis.
abstract: Smooth muscle cell proliferation plays a major role in the genesis of restenosis after angioplasty or vascular injury. Controlled release of appropriate drugs alone and in combinations is one approach for treating coronary obstructions, balloon angioplasty, restenosis associated with thrombosis, and calcification. We demonstrated the possibility of encapsulating taxol-loaded polylactic acid (PLA) microspheres within heparin-chitosan spheres to develop a prolonged release co-matrix form. The in vitro release profile of taxol and heparin from this co-matrix system was monitored in phosphate buffered saline pH 7.4, using an ultraviolet spectrophotometer. The amount of taxol/heparin release was initially much higher, followed by a constant slow release profile for a prolonged period. The initial burst release of taxol (15.8%) and heparin (32.7%) from the co-matrix was modified with polyethylene glycol coatings (13.5% and 25.4%, respectively, for 24 hr). From scanning electron microscopy studies, it appears that these drugs diffuse out slowly to the dissolution medium through the micropores of the co-matrix. However, the surface micropores were modified with polyethylene glycol (PEG) coatings for a constant slow release profile. This PEG-coated PLA/chitosan co-matrix may target drug combinations having synergestic effects for prolonged periods to treat restenosis.
authors.affiliation: Department of Cardiology, University of Minnesota, Minneapolis 55455, USA. chand025@tc.umn.edu
authors.forename: T
authors.initials: T
authors.lastname: Chandy
authors.forename: G H
authors.initials: GH
authors.lastname: Rao
authors.forename: R F
authors.initials: RF
authors.lastname: Wilson
authors.forename: G S
authors.initials: GS
authors.lastname: Das
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000627:therapeutic use; D002686:Chitin / Q000031:analogs & derivatives / Q000737:chemistry*; D048271:Chitosan; D003692:Delayed-Action Preparations; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005079:Excipients; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006493:Heparin / Q000008:administration & dosage* / Q000627:therapeutic use; D019344:Lactic Acid / Q000737:chemistry*; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D017239:Paclitaxel / Q000008:administration & dosage* / Q000627:therapeutic use; D010316:Particle Size; D011091:Polyesters; D011108:Polymers / Q000737:chemistry*; D012995:Solubility; D013918:Thrombin Time
chemical_list: D000925:Anticoagulants; D000972:Antineoplastic Agents, Phytogenic; D003692:Delayed-Action Preparations; D005079:Excipients; D011091:Polyesters; D011108:Polymers; D002686:Chitin; D019344:Lactic Acid; C033616:poly(lactide); D006493:Heparin; D048271:Chitosan; D017239:Paclitaxel